Testing panitumumab-IRDye800 to help surgeons see ovarian cancer tissue during surgery
Tests panitumumab-IRDye800 as a surgical imaging agent in adults with ovarian cancer.
Plain-language title generated from the registry record
Registry title: A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
Key facts
- Where
- Birmingham, United StatesSee the site
- Phase
- Phase 1
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT07919509
- Record updated
- 5 November 2026
- Original description
This is a pilot project to determine the safety and feasibility of using panitumumab-IRDye800 to detect cancerous tissue compared to normal surrounding tissue in participants with ovarian cancer undergoing surgical resection. This study is an extension of the work previously done using this agent in patients with squamous cell carcinoma (SCC) of the head and neck, exploring its utility in a different cancer type.Read full original descriptionShow less
Pilot Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
This is a pilot project to determine the safety and feasibility of using panitumumab-IRDye800 to detect cancerous tissue compared to normal surrounding tissue in participants with ovarian cancer undergoing surgical resection. This study is an extension of the work previously done using this agent in patients with squamous cell carcinoma (SCC) of the head and neck, exploring its utility in a different cancer type.
Inclusion: Biopsy-confirmed diagnosis of ovarian cancer; Diagnosis of any stage; Diagnosis of any histology; Planning to undergo surgical resection via any modality (i.e., open, laparoscopic, robotic) with primary cytoreduction or interval debulking following neoadjuvant chemotherapy; Age ≥ 18 years; ECOG 1; Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:; Hemoglobin ≥ 9 gm/dL; Absolute Neutrophil Count ≥ 1500; White Blood Cell count > 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range.
Exclusion: Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800; Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF; Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents; History of infusion reactions to any monoclonal antibody therapies; Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis; Evidence of QT prolongation on pretreatment EKG (greater than 440 ms in males or greater than 450 ms in females); Magnesium or potassium lower than the normal institutional values; Pregnant or breast-feeding; TSH > 13 micro International Units/mL.